WallStSmart

Coinbase Global Inc (COIN)vsEli Lilly and Company (LLY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 847% more annual revenue ($65.18B vs $6.88B). LLY leads profitability with a 31.7% profit margin vs 18.3%. COIN appears more attractively valued with a PEG of 0.75. LLY earns a higher WallStSmart Score of 80/100 (A-).

COIN

Buy

60

out of 100

Grade: C

Growth: 5.3Profit: 6.5Value: 9.3Quality: 7.0
Piotroski: 2/9Altman Z: 1.78

LLY

Exceptional Buy

80

out of 100

Grade: A-

Growth: 10.0Profit: 10.0Value: 8.7Quality: 8.0
Piotroski: 6/9Altman Z: 2.06
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

COINUndervalued (+26.4%)

Margin of Safety

+26.4%

Fair Value

$208.26

Current Price

$181.10

$27.16 discount

UndervaluedFair: $208.26Overvalued
LLYUndervalued (+14.0%)

Margin of Safety

+14.0%

Fair Value

$1065.17

Current Price

$916.31

$148.86 discount

UndervaluedFair: $1065.17Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COIN2 strengths · Avg: 8.0/10
PEG RatioValuation
0.758/10

Growing faster than its price suggests

Free Cash FlowQuality
$3.07B8/10

Generating 3.1B in free cash flow

LLY6 strengths · Avg: 10.0/10
Market CapQuality
$808.22B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
101.2%10/10

Every $100 of equity generates 101 in profit

Profit MarginProfitability
31.7%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability
44.9%10/10

Strong operational efficiency at 44.9%

Revenue GrowthGrowth
42.6%10/10

Revenue surging 42.6% year-over-year

EPS GrowthGrowth
51.4%10/10

Earnings expanding 51.4% YoY

Areas to Watch

COIN4 concerns · Avg: 3.3/10
EPS GrowthGrowth
4.3%4/10

4.3% earnings growth

Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
40.7x2/10

Premium valuation, high expectations priced in

LLY3 concerns · Avg: 3.0/10
P/E RatioValuation
39.7x4/10

Premium valuation, high expectations priced in

Debt/EquityHealth
1.603/10

Elevated debt levels

Price/BookValuation
30.9x2/10

Trading at 30.9x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : COIN

The strongest argument for COIN centers on PEG Ratio, Free Cash Flow. Profitability is solid with margins at 18.3% and operating margin at 11.3%. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.

Bear Case : COIN

The primary concerns for COIN are EPS Growth, Altman Z-Score, Piotroski F-Score. A P/E of 40.7x leaves little room for execution misses.

Bear Case : LLY

The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.

Key Dynamics to Monitor

COIN profiles as a declining stock while LLY is a growth play — different risk/reward profiles.

COIN carries more volatility with a beta of 3.71 — expect wider price swings.

LLY is growing revenue faster at 42.6% — sustainability is the question.

COIN generates stronger free cash flow (3.1B), providing more financial flexibility.

Bottom Line

LLY scores higher overall (80/100 vs 60/100), backed by strong 31.7% margins and 42.6% revenue growth. COIN offers better value entry with a 26.4% margin of safety. Both earn "Exceptional Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Coinbase Global Inc

FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA

Coinbase Global, Inc. provides financial infrastructure and technology for the crypto economy. The company is headquartered in Wilmington, Delaware.

Visit Website →

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Want to dig deeper into these stocks?